NASDAQ:ITCIIntra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ITCI shares have increased by 18.5% and is now trading at $21.05. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intra-Cellular Therapies.

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Intra-Cellular Therapies.

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.93) by $0.20. The biopharmaceutical company earned $1.08 million during the quarter, compared to the consensus estimate of $1.75 million. View Intra-Cellular Therapies' earnings history.

10 Wall Street analysts have issued twelve-month target prices for Intra-Cellular Therapies' shares. Their forecasts range from $16.00 to $68.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $37.13 in the next twelve months. This suggests a possible upside of 76.4% from the stock's current price. View analysts' price targets for Intra-Cellular Therapies.

Media headlines about ITCI stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutIntra-Cellular Therapies.

Some companies that are related to Intra-Cellular Therapies include United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), PPD (SDGR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Evotec (EVTCY) and ChemoCentryx (CCXI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Amarin (AMRN), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), AbbVie (ABBV), Clovis Oncology (CLVS), Novavax (NVAX), Myovant Sciences (MYOV), ACADIA Pharmaceuticals (ACAD) and Karyopharm Therapeutics (KPTI).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.70%), Wasatch Advisors Inc. (4.43%), State Street Corp (1.86%), Samlyn Capital LLC (1.74%), Schroder Investment Management Group (1.68%) and St. Louis Trust Co (1.33%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View institutional ownership trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Voloridge Investment Management LLC, General American Investors Co. Inc., DCF Advisers LLC, CSS LLC IL, and UBS Group AG. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, and Sharon Mates. View insider buying and selling activity for Intra-Cellular Therapies.

ITCI stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Ikarian Capital LLC, Samlyn Capital LLC, St. Louis Trust Co, BlackRock Inc., Alyeska Investment Group L.P., Schroder Investment Management Group, and Invesco Ltd.. View insider buying and selling activity for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $21.05.

Intra-Cellular Therapies has a market capitalization of $1.40 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]